Matrix metalloproteinase 9 is involved in airway inflammation in cough variant asthma

Ma,Hui-Ping; Li,Wei; Liu,Xiao-Min

doi:10.3892/etm.2014.1903

Matrix metalloproteinase 9 is involved in airway inflammation in cough variant asthma

Authors:
- Hui-Ping Ma
- Wei Li
- Xiao-Min Liu
View Affiliations

Affiliations: Department of Respiratory Medicine, Jining No. 1 People's Hospital, Jining, Shandong 272111, P.R. China, Department of Otorhinolaryngology, Jining No. 1 People's Hospital, Jining, Shandong 272111, P.R. China, Department of Respiratory Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: August 13, 2014 https://doi.org/10.3892/etm.2014.1903
Pages: 1197-1200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have revealed the role of matrix metalloproteinase 9 (MMP9) in asthma and chronic obstructive pulmonary disease (COPD). However, its role in airway inflammation in cough variant asthma (CVA) remains unknown. In the present study, variations in the levels of MMP9 and interleukin (IL)‑5 in the induced sputum of patients with CVA prior to and following therapy with inhaled corticosteroid and long‑acting β2‑agonist (ICS/LABA), were detected. The levels of IL‑5 and percentage of eosinophils (EOS) in the induced sputum from patients with CVA were significantly higher than those in the control group of healthy individuals. The levels of MMP9 in the induced sputum from patients with CVA were also significantly higher than those in the control group. Following treatment with ICS/LABA for 6‑9 months, the levels of MMP9 and IL‑5, as well as the percentage of EOS, in the induced sputum from patients with CVA had significantly decreased. Thus, MMP9 may be an important biomarker in the airway inflammation of CVA.

View Figures

View References

1	Fujimura M, Ogawa H, Nishizawa Y and Nishi K: Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma? Thorax. 58:14–18. 2003. View Article : Google Scholar : PubMed/NCBI
2	Lai K, Chen R, Lin J, et al: A prospective, multicenter survey on causes of chronic cough in China. Chest. 143:613–620. 2013.PubMed/NCBI
3	Matsumoto H, Niimi A, Tabuena RP, et al: Airway wall thickening in patients with cough variant asthma and nonasthmatic chronic cough. Chest. 131:1042–1049. 2007. View Article : Google Scholar : PubMed/NCBI
4	Niimi A: Structural changes in the airways: cause or effect of chronic cough? Pulm Pharmacol Ther. 24:328–333. 2011. View Article : Google Scholar : PubMed/NCBI
5	Bratcher PE, Weathington NM, Nick HJ, et al: MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS One. 7:e418812012. View Article : Google Scholar : PubMed/NCBI
6	Vandenbroucke RE, Dejonckheere E and Libert C: A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur Respir J. 38:1200–1214. 2011. View Article : Google Scholar : PubMed/NCBI
7	Chaudhuri R, McSharry C, Brady J, et al: Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: relationship to disease severity. J Allergy Clin Immunol. 129:655–663. 2012. View Article : Google Scholar : PubMed/NCBI
8	Oka S, Furukawa H, Shimada K, et al: Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease. BMC Immunol. 14:92013. View Article : Google Scholar : PubMed/NCBI
9	Hu C, Wang J, Xu Y, et al: Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene. 517:65–71. 2013. View Article : Google Scholar : PubMed/NCBI
10	Craig VJ, Quintero PA, Fyfe SE, et al: Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury. J Immunol. 190:4283–4296. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ko FW, Diba C, Roth M, et al: A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest. 127:1919–1927. 2005. View Article : Google Scholar : PubMed/NCBI
12	Castano R, Miedinger D, Maghni K, et al: Matrix metalloproteinase-9 increases in the sputum from allergic occupational asthma patients after specific inhalation challenge. Int Arch Allergy Immunol. 160:161–164. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hong Z, Lin YM, Qin X and Peng JL: Serum MMP-9 is elevated in children with asthma. Mol Med Rep. 5:462–464. 2012.PubMed/NCBI
14	Page K, Ledford JR, Zhou P and Wills-Karp M: A TLR2 agonist in German cockroach frass activates MMP-9 release and is protective against allergic inflammation in mice. J Immunol. 183:3400–3408. 2009. View Article : Google Scholar : PubMed/NCBI
15	Asthma Workgroup, Chinese Society, Respiratory, Diseases (CSRD), Chinese Medical, Association. The Chinese national guidelines on diagnosis and management of cough (December 2010). Chin Med J (Engl). 124:3207–3219. 2011.PubMed/NCBI
16	De Diego A, Martínez E, Perpiñá M, et al: Airway inflammation and cough sensitivity in cough-variant asthma. Allergy. 60:1407–1411. 2005.PubMed/NCBI
17	Yoo Y, Koh YY, Kang H, et al: Sputum eosinophil counts and eosinophil cationic protein levels in cough-variant asthma and in classic asthma, and their relationships to airway hypersensitivity or maximal airway response to methacholine. Allergy. 59:1055–1062. 2004. View Article : Google Scholar
18	Yang MS, Lee HS, Kim MH, et al: Rhinitis patients with sputum eosinophilia show decreased lung function in the absence of airway hyperresponsiveness. Allergy Asthma Immunol Res. 5:232–238. 2013. View Article : Google Scholar : PubMed/NCBI
19	de Borja Callejas F, Picado C, Martínez-Antón A, et al: Differential expression of remodeling markers by tissue structure in nasal polyposis. Am J Rhinol Allergy. 27:e69–e74. 2013.PubMed/NCBI